Compare Fubotv Inc (FUBO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Illumina, Inc. — how do they compare? Fubotv Inc trades at $9.2 (market cap $1.02B), while Illumina, Inc. trades at $273.58 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 39.2× Fubotv Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Illumina, Inc. for 83 Days on average.
| FUBO | ILMN | |
|---|---|---|
Market Cap | $1.02B | $39.95B |
Volume | 978,631 | 3,169,503 |
Sector | Media | Health |
52-Week High | $48.96 | $293.69 |
52-Week Low | $8.09 | $91.00 |
Typical Hold Time | 35 Days | 83 Days |
Enterprise Value | $1.19B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.25, up 4.76% today, showing technical bearish signals with mixed earnings performance. The company reported Q2 2026 EPS of -$0.25, beating expectations, but missed in Q4 2025. Revenue growth has been strong, reaching $1.62B in 2024 with improving profit margins. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a speculative opportunity with deep valuation discounts (P/E 2.43, P/S 0.19) but faces execution risks amid persistent cash burn. Analyst consensus is mixed with 47% buy ratings and $63.38 price target, representing significant upside potential if turnaround succeeds. Key risks include competitive pressure and path to sustained profitability.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
